Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ACTU with free AI briefings, catalyst countdowns, and dilution alerts.

ACTU · Actuate Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.1M Cash on Hand
1.7mo Cash Runway
Follow ACTU by email Get an email when ACTU reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ACTU, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Nab-paclitaxel Cancer Phase 2 · NCT03678883 Active not recruiting
Losartan Pancreatic Adenocarcinoma Phase 2 · NCT05077800 Active not recruiting
Irinotecan Cancer Phase 2 · NCT03678883 Active not recruiting
Gemcitabine Hydrochloride Cancer Phase 2 · NCT03678883 Active not recruiting
FOLFIRNINOX Pancreatic Adenocarcinoma Phase 2 · NCT05077800 Active not recruiting
Elraglusib Advanced Malignant Solid Tumor Phase 1/2 · NCT07714395 Not yet recruiting
Doxorubicin Cancer Phase 2 · NCT03678883 Active not recruiting
Cytotoxic Chemotherapeutic Agent Pancreatic Adenocarcinoma Phase 1 · NCT06896188 Recruiting

Also used in these trials (approved or third-party drugs, not ACTU's own candidates): Paclitaxel, Ruxolitinib, Retifanlimab, Pembrolizumab, Lomustine, Docetaxel Anhydrous, Carboplatin, Cyclophosphamide, Temozolomide, Topotecan.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ACTU holds $2.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.7M/quarter from operations, an estimated runway of 1.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACTU files for a raise →

👥 Who Owns ACTU

Insiders 22.8% Other 5%+ holders 10% Institutions (53 holders) 24.4% Public and other holders 42.8%
HolderTypeShares% of sharesAs of
Aaron G.L. Fletcher
Director, 10% owner · +151,840 options
Insider 10,196,456 16.89% 2025-06-27
Bios Equity COF, LP
Director, 10% owner · +121,840 options
Includes shares also reported by Aaron G.L. Fletcher, counted once
Insider 10,196,456 16.89% 2025-06-27
Leslie W. Kreis
Director, 10% owner · +121,840 options
Includes shares also reported by Aaron G.L. Fletcher, counted once
Insider 10,196,456 16.89% 2025-06-27
Hexstone Capital LLC 5%+ holder (13G) 4,225,352 7.00% 2026-10-27
Todd S Thomson
Director · +216,411 options
Insider 2,354,344 3.90% 2026-01-05
Voss Capital, LP 5%+ holder (13G) 1,814,263 3.00% 2026-03-31
Daniel M Schmitt
President, CEO and Director, Director · +511,707 options
Insider 1,073,300 1.78% 2026-10-28
Bios 2024 Co-Invest, LP
Director
Insider 125,000 0.21% 2024-08-14

Share count 60,382,824 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ACTU picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACTU and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.